Key Highlights

  • The third-quarter net loss was USD 128 million, or USD 1.00 per share, against USD 135 million, or USD 1.27 per share, a year earlier.
  • Revenue dropped to USD 9 million from USD 26 million, and operating expenses declined to USD 140 million from USD 168 million.
  • Cash, cash equivalents and marketable securities came to USD 694 million at September 30, 2026, prior to an October offering of 16.4 million shares priced at USD 17.50.
  • Management believes cash plus October proceeds can fund planned operations into 2029, though it still expects to need substantial further funding.

Revenue Falls Sharply as Spending Pulls Back

Arcus Biosciences (NYSE:RCUS) is a late clinical-stage biopharmaceutical company working on cancer and immunology treatments. It filed its Quarterly Report on November 4, 2026, covering the period ended September 30, 2026. Revenue was USD 9 million compared with USD 26 million, and nine-month revenue came to USD 67 million versus USD 214 million, a figure that included USD 192 million of license and development services revenue in the 2025 period. Research and Development expense eased to USD 117 million from USD 141 million, while the nine-month net loss widened to USD 347 million from USD 247 million. General and administrative spending was USD 23 million against USD 27 million, and interest and other income dropped to USD 6 million from USD 10 million. The company has no product sales, with all revenue so far coming from collaboration, license and research arrangements.

Offering Proceeds and a Funding Runway Into 2029

In October 2026, the company sold 16.4 million shares at USD 17.50 in an underwritten offering, bringing in gross proceeds of about USD 288 million before costs. Management says the cash held at September 30, together with those proceeds, supports planned operations into 2029. Weighted shares climbed to 127.4 million from 106.5 million. The filing states that substantial additional funding will still be required to continue development, and the company expects to draw on equity, Debt or partnerships. Gilead Sciences (NASDAQ:GILD) saw its option rights under the 2020 collaboration lapse on July 14, 2026, after it declined to make the option continuation payment. Of a USD 30 million milestone from Taiho, USD 15 million came in during the third quarter, and the remaining USD 15 million is due in the first quarter of 2027.

Casdatifan Response Data and a Halted Phase 3 Study

In October 2026, Arcus Biosciences (NYSE:RCUS) reported casdatifan results in clear cell renal cell carcinoma. Among first-line patients, casdatifan combined with zimberelimab (30 patients) achieved a 50% confirmed response rate. The casdatifan and cabozantinib pairing in 43 second-line patients produced median progression-free survival of 14.5 months and a 44% confirmed response rate. In 121 late-line patients on monotherapy, median overall survival was 35 months, median progression-free survival 13 months and the response rate 36%. These are early cohort results rather than randomized comparisons. In August 2026, the company stopped the Phase 3 PACIFIC-8 study of domvanalimab and ended its agreement with AstraZeneca (NYSE:AZN).

Where Things Stand

Funding looks adequate for now, though it still depends on new capital. Arcus Biosciences (NYSE:RCUS) reported a USD 128 million quarterly loss on revenue of just USD 9 million, so its runway rests on the cash it holds and the October offering. Management ties funding to operations into 2029 but says substantial further funding will be needed. Key markers ahead are casdatifan trial progress and any new partner Economics now that Gilead's option rights have ended.